Novartis wants to blaze a trail in breast cancer with PIK3 drug

Novartis is preparing to file its PIK3 drug combination for a certain group of breast cancer patients, after late stage trial results showed its alpelisib combination stopped the disease progressing for twice as long as standard therapy, with “manageable” side effects.